VeroScience

VeroScience is a biotechnology company that develops novel and effective therapies for chronic debilitating diseases such as T2DM, metabolic syndrome, autoimmune disease, and cancer through interdisciplinary research. VeroScience developed Cycloset®, a FDA-approved, sympatholytic dopamine receptor agonist for T2DM.  Cycloset improves insulin action and reduces day-long postprandial hyperglycemia without raising plasma insulin. In a large, one-year, controlled cardiovascular outcomes trial, Cycloset therapy was associated with a significant 42% relative-risk reduction of a prespecified composite cardiovascular endpoint.